REGULATORY
Orlistat in Line for Approval as Japan’s 1st Nonprescription Obesity Drug after 4-Year Review
By Tatsuya Otsuka November 29, 2022
A health ministry panel on November 28 cleared what is now set to be the first nonprescription obesity treatment in Japan. The drug is expected to gain the official stamp of approval at the end…

LATEST

November 29, 2022
KM Biologics plans to file its inactivated COVID-19 vaccine KD-414 in Japan in the April-June quarter of 2023, a company official revealed at an academic symposium on November 27.KD-414 is currently being investigated in a PIII study in Japan and…
November 29, 2022
The Japan Society for the Study of Obesity (JASSO) plans to put out recommendations to ensure the appropriate use of Novo Nordisk Pharma’s GLP-1 agent semaglutide, which is pending approval for obesity in Japan, once…
November 29, 2022
A project team of the ruling Liberal Democratic Party (LDP) aiming to foster Japan’s strengths in drug discovery will call on the health minister to limit the coverage of next year’s “off-year” price revision to…
By Izuru Ando

While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…

By Philip Carrigan

As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…

A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…

Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA